Design,synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm

Structure-based design has led to the synthesis of a novel analogue of GS-4071, an influenza neuraminidase inhibitor, in which the basic amino group has been replaced by a hydrophobic vinyl group. An X-ray co-crystal structure of the new inhibitor (K(i)=45 nM) bound to the active site shows that the vinyl group occupies the same subsite as the amino group in GS-4071.     

Carbon dioxide assimilation by leaves, isolated chloroplasts, and ribulose bisphosphate carboxylase from spinach

The relationship between rate of photosynthesis and CO(2) concentration has been reinvestigated using isolated spinach (Spinacia oleracea) chloroplasts. The apparently low CO(2) concentration required for half-maximal photosynthesis is shown to result partly from a ceiling imposed by electron transport. In double reciprocal plots of rate against CO(2) concentration, this ceiling results in departures from linearity at high CO(2) concentrations. If these rate limitations are disregarded in extrapolation the "true" CO(2) concentration required for half maximal carboxylation by intact chloroplasts is approximately 46 mum (CO(2)).When assayed under comparable conditions, ribulose bisphosphate carboxylase from these chloroplasts also shows an apparent Km (CO(2)) of approximately 46 mum, suggesting that its characteristics are not modified by extraction. An improved assay for ribulose bisphosphate carboxylase yielded rates of carboxylation considerably higher than those previously reported, the highest maximal velocities recorded approaching 1000 mumoles CO(2) fixed mg(-1) chlorophyll hr(-1) at 20 C. With such Km and V(max), values the carboxylase would be able to achieve, at concentrations of CO(2) less than atmospheric, rates of CO(2) fixation equal to those displayed by the parent tissue or by the average plant under favorable conditions in its natural environment.     

The functional antagonist Met-RANTES: A modified agonist that induces differential CCR5 trafficking

CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.     

Structural insights into the inhibited states of the Mer receptor tyrosine kinase

The mammalian ortholog of the retroviral oncogene v-Eyk, and a receptor tyrosine kinase upstream of antiapoptotic and transforming signals, Mer (MerTK) is a mediator of the phagocytic process, being involved in retinal and immune cell clearance and platelet aggregation. Mer knockout mice are viable and are protected from epinephrine-induced pulmonary thromboembolism and ferric chloride-induced thrombosis. Mer overexpression, on the other hand, is associated with numerous carcinomas. Although Mer adaptor proteins and signaling pathways have been identified, it remains unclear how Mer initiates phagocytosis. When bound to its nucleotide cofactor, the high-resolution structure of Mer shows an autoinhibited αC-Glu-out conformation with insertion of an activation loop residue into the active site. Mer complexed with compound-52 (C52: 2-(2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine), a ligand identified from a focused library, retains its DFG-Asp-in and αC-Glu-out conformation, but acquires other conformational changes. The αC helix and DFGL region is closer to the hinge region and the ethanolamine moiety of C52 binds in the groove formed between Leu593 and Val601 of the P-loop, causing a compression of the active site pocket. These conformational states reveal the mechanisms of autoinhibition, the pathophysiological basis of disease-causing mutations, and a platform for the development of chemical probes.     

A dual-targeting PDGFRβ/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

Targeting angiogenesis is a promising approach to the treatment of solid tumors and age-related macular degeneration (AMD). Inhibition of vascularization has been validated by the successful marketing of monoclonal antibodies (mAbs) that target specific growth factors or their receptors, but there is considerable room for improvement in existing therapies. Combination of mAbs targeting both the VeGF and pDGF pathways has the potential to increase the efficacy of anti-angiogenic therapy without the accompanying toxicities of tyrosine kinase inhibitors and the inability to combine efficiently with traditional chemotherapeutics. However, development costs and regulatory issues have limited the use of combinatorial approaches for the generation of more efficacious treatments.The concept of mediating disease pathology by targeting two antigens with one therapeutic was proposed over two decades ago. While mAbs are particularly suitable candidates for a dual-targeting approach, engineering bispecificity into one molecule can be difficult due to issues with expression and stability, which play a significant role in manufacturability. Here, we address these issues upstream in the process of developing a bispecific antibody (bsAb). Single-chain antibody fragments (scFvs) targeting pDGFRβ and VeGF-A were selected for superior stability. the scFvs were fused to both termini of human Fc to generate a bispecific, tetravalent molecule. resulting molecule displays potent activity, binds both targets simultaneously, and is stable in serum. assembly of a bsAb using stable monomeric units allowed development of an anti-pDGFRB/VeGF-A antibody capable of attenuating angiogenesis through two distinct pathways and represents an efficient method for rapid engineering of dual-targeting molecules.Key words: bispecific, antibody, PDGFRβ, VEGF-A, stability, angiogenesis     

Analysis of SMN-neurite granules: Core Cajal body components are absent from SMN-cytoplasmic complexes

Childhood spinal muscular atrophy (SMA) is caused by a reduction in survival motor neuron (SMN) protein. SMN is a ubiquitously expressed house keeping protein that is involved in RNA production and processing. However, although SMN is expressed in every cell type, only the lower motor neurons of the spinal cord are degraded in SMA. It remains unclear why this is the case. Recently, SMN has been linked to the axonal transport of β-actin mRNA from the cell body down to the growth cones. β-Actin is transported actively in neurite granules (NGs). However, it remains unclear which known SMN-binding partners are present in these SMN-NGs. To address this we have analysed SMN-NGs in a human neuronal cell line, SH-SY5Y, using antibodies against the majority of reported SMN-binding partners, including: Gemin2, Gemin3, Gemin4, Gemin5, Gemin6, Gemin7, Sm core proteins, fibrillarin, EWS, PFNII, Unrip and ZPR1. The obtained results highlight the metamorphic nature of the SMN complex, suggesting that not all the “core” SMN-binding proteins are transported in SMN-NGs.     

A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis

Introduction

Preclinical work has suggested that IL-1 plays a critical role in the pathogenesis of rheumatoid arthritis (RA). The objective of the present study was to determine the effect of a long-acting IL-1 receptor inhibitor, AMG 108, in a double-blind, placebo-controlled, parallel-dosing study in patients with active RA who were receiving stable methotrexate (15 to 25 mg/week).

Methods

Patients were randomized equally to receive placebo or 50, 125, or 250 mg AMG 108 subcutaneously every 4 weeks for 6 months. The primary efficacy endpoint was a 20% improvement in the American College of Rheumatology response (ACR20) at week 24; other efficacy endpoints included the ACR50, the ACR70, and the RA disease activity score (28-joint count Disease Activity Score) responses, patient-reported outcomes, and pharmacokinetic parameters. Safety endpoints included treatment-emergent adverse events (AEs), infectious AEs, serious AEs, serious infections, injection site reactions, laboratory abnormalities, and antibodies to AMG 108.

Results

Of 813 patients enrolled in the study, 204 patients were randomized to the 50 mg group, 203 to the 125 mg group, 203 to the 250 mg group, and 203 to placebo. At week 24, 40.4% of the 250 mg group, 36% of the 125 mg group, 30.9% of the 50 mg group, and 29.1% of the placebo group achieved an ACR20 (P = 0.022, 250 mg vs. placebo). Of the individual ACR components, numerical dose-dependent improvements were only seen in tender joint counts, pain (visual analog scale), and the acute phase reactants, erythrocyte sedimentation rate and C-reactive protein. No dose-related increase was observed in the incidence of treatment-emergent AEs. No deaths were reported, and the incidence of AEs and infections, serious AEs and infections, and withdrawals from study for safety were similar in the AMG 108 and placebo groups.

Conclusions

This large double-blind randomized trial with a long-acting IL-1 receptor blocker, AMG 108, is consistent with the experience of other IL-1 blockers, represents a definitive experiment showing that IL-1 inhibition provides only moderate symptomatic amelioration of arthritis activity in the majority of RA patients, and provides an answer to a question that has been discussed for many years in the rheumatologic community.

Trial Registration

ClinicalTrials.gov NCT00293826     

Addressing Accuracy and Precision Issues in iTRAQ Quantitation

iTRAQ (isobaric tags for relative or absolute quantitation) is a mass spectrometry technology that allows quantitative comparison of protein abundance by measuring peak intensities of reporter ions released from iTRAQ-tagged peptides by fragmentation during MS/MS. However, current data analysis techniques for iTRAQ struggle to report reliable relative protein abundance estimates and suffer with problems of precision and accuracy. The precision of the data is affected by variance heterogeneity: low signal data have higher relative variability; however, low abundance peptides dominate data sets. Accuracy is compromised as ratios are compressed toward 1, leading to underestimation of the ratio. This study investigated both issues and proposed a methodology that combines the peptide measurements to give a robust protein estimate even when the data for the protein are sparse or at low intensity. Our data indicated that ratio compression arises from contamination during precursor ion selection, which occurs at a consistent proportion within an experiment and thus results in a linear relationship between expected and observed ratios. We proposed that a correction factor can be calculated from spiked proteins at known ratios. Then we demonstrated that variance heterogeneity is present in iTRAQ data sets irrespective of the analytical packages, LC-MS/MS instrumentation, and iTRAQ labeling kit (4-plex or 8-plex) used. We proposed using an additive-multiplicative error model for peak intensities in MS/MS quantitation and demonstrated that a variance-stabilizing normalization is able to address the error structure and stabilize the variance across the entire intensity range. The resulting uniform variance structure simplifies the downstream analysis. Heterogeneity of variance consistent with an additive-multiplicative model has been reported in other MS-based quantitation including fields outside of proteomics; consequently the variance-stabilizing normalization methodology has the potential to increase the capabilities of MS in quantitation across diverse areas of biology and chemistry.Different techniques are being used and developed in the field of proteomics to allow quantitative comparison of samples between one state and another. These can be divided into gel- (1–4) or mass spectrometry-based (5–8) techniques. Comparative studies have found that each technique has strengths and weaknesses and plays a complementary role in proteomics (9, 10). There is significant interest in stable isotope labeling strategies of proteins or peptides as with every measurement there is the potential to use an internal reference allowing relative quantitation comparison, which significantly increases sensitivity of detection of change in abundance. Isobaric labeling techniques such as tandem mass tags (11, 12) or isobaric tags for relative or absolute quantitation (iTRAQ)¹ (13, 14) allow multiplexing of four, six and eight separately labeled samples within one experiment. In contrast to most other quantitative proteomics methods where precursor ion intensities are measured, here the measurement and ensuing quantitation of iTRAQ reporter ions occurs after fragmentation of the precursor ion. Differentially labeled peptides are selected in MS as a single mass precursor ion as the size difference of the tags is equalized by a balance group. The reporter ions are only liberated in MS/MS after the reporter ion and balance groups fragment from the labeled peptides during CID. iTRAQ has been applied to a wide range of biological applications from bacteria under nitrate stress (15) to mouse models of cerebellar dysfunction (16).For the majority of MS-based quantitation methods (including MS/MS-based methods like iTRAQ), the measurements are made at the peptide level and then combined to compute a summarized value for the protein from which they arose. An advantage is that the protein can be identified and quantified from data of multiple peptides often with multiple values per distinct peptide, thereby enhancing confidence in both identity and the abundance. However, the question arises of how to summarize the peptide readings to obtain an estimate of the protein ratio. This will involve some sort of averaging, and we need to consider the distribution of the data, in particular the following three aspects. (i) Are the data centered around a single mode (which would be related to the true protein quantitation), or are there phenomena that make them multimodal? (ii) Are the data approximately symmetric (non-skewed) around the mode? (iii) Are there outliers? In the case of multimodality, it is recommended that an effort be made to separate the various phenomena into their separate variables and to dissect the multimodality. Li et al. (17) developed ASAP ratio for ICAT data that includes a complex data combination strategy. Peptide abundance ratios are calculated by combining data from multiple fractions across MS runs and then averaging across peptides to give an abundance ratio for each parent protein. GPS Explorer, a software package developed for iTRAQ, assumes normality in the peptide ratio for a protein once an outlier filter is applied (18). The iTRAQ package ProQuant assumes that peptide ratio data for a protein follow a log-normal distribution (19). Averaging can be via mean (20), weighted average (21, 22), or weighted correlation (23). Some of these methods try to take into account the varying precision of the peptide measurements. There are many different ideas of how to process peptide data, but as yet no systematic study has been completed to guide analysis and ensure the methods being utilized are appropriate.The quality of a quantitation method can be considered in terms of precision, which refers to how well repeated measurements agree with each other, and accuracy, which refers to how much they on average deviate from the true value. Both of these types of variability are inherent to the measurement process. Precision is affected by random errors, non-reproducible and unpredictable fluctuations around the true value. (In)accuracy, by contrast, is caused by systematic biases that go consistently in the same direction. In iTRAQ, systematic biases can arise because of inconsistencies in iTRAQ labeling efficiency and protein digestion (22). Typically, ratiometric normalization has been used to address this tag bias where all peptide ratios are multiplied by a global normalization factor determined to center the ratio distribution on 1 (19, 22). Even after such normalization, concerns have been raised that iTRAQ has imperfect accuracy with ratios shrunken toward 1, and this underestimation has been reported across multiple MS platforms (23–27). It has been suggested that this underestimation arises from co-eluting peptides with similar m/z values, which are co-selected during ion selection and co-fragmented during CID (23, 27). As the majority of these will be at a 1:1 ratio across the reporter ion tags (as required for normalization in iTRAQ experiments), they will contribute a background value equally to each of the iTRAQ reporter ion signals and diminish the computed ratios.With regard to random errors, iTRAQ data are seen to exhibit heterogeneity of variance; that is the variance of the signal depends on its mean. In particular, the coefficient of variation (CV) is higher in data from low intensity peaks than in data from high intensity peaks (16, 22, 23). This has also been observed in other MS-based quantitation techniques when quantifying from the MS signal (28–30). Different approaches have been proposed to model the variance heterogeneity. Pavelka et al. (31) used a power law global error model in conjunction with quantitation data derived from spectral counts. Other authors have proposed that the higher CV at low signal arises from the majority of MS instrumentation measuring ion counts as whole numbers (32). Anderle et al. (28) described a two-component error model in which Poisson statistics of ion counts measured as whole numbers dominate at the low intensity end of the dynamic range and multiplicative effects dominate at the high intensity end and demonstrated its fit to label-free LC-MS quantitation data. Previously, in the 1990s, Rocke and Lorenzato (29) proposed a two-component additive-multiplicative error model in an environmental toxin monitoring study utilizing gas chromatography MS.How can the variance heterogeneity be addressed in the data analysis? Some of the current approaches include outlier removal (18, 25), weighted means (21, 22), inclusion filters (16, 22), logarithmic transformation (19), and weighted correlation analysis (23). Outlier removal methods, for example using Dixon''s test, assume a normal distribution for which there is little empirical basis. The inclusion filter method, where low intensity data are excluded, reduces the protein coverage considerably if the heterogeneity is to be significantly reduced. The weighted mean method results in higher intensity readings contributing more to the weighted mean than readings from low intensity readings. Filtering, outlier removal, and weighted methods are of limited use for peptides for which only a few low intensity readings were made; however, such cases typically dominate the data sets. Even with a logarithmic transformation, heterogeneity has been reported for iTRAQ data (16, 19, 22). Current methods struggle to address the issue and to maintain sensitivity.Here we investigate the data analysis issues that relate to precision and accuracy in quantitation and propose a robust methodology that is designed to make use of all data without ad hoc filtering rules. The additive-multiplicative model mentioned above motivates the so-called generalized logarithm transformation, a transformation that addresses heterogeneity of variance by approximately stabilizing the variance of the transformed signal across its whole dynamic range (33). Huber et al. (33) provided an open source software package, variance-stabilizing normalization (VSN), that determines the data-dependent transformation parameters. Here we report that the application of this transformation is beneficial for the analysis of iTRAQ data. We investigated the error structure of iTRAQ quantitation data using different peak identification and quantitation packages, LC-MS/MS data collection systems, and both the 4-plex and 8-plex iTRAQ systems. The usefulness of the VSN transformation to address heterogeneity of variance was demonstrated. Furthermore, we considered the correlations between multiple, peptide-level readings for the same protein and proposed a method to summarize them to a protein abundance estimate. We considered same-same comparisons to assess the magnitude of experimental variability and then used a set of complex biological samples whose biology has been well characterized to assess the power of the method to detect true differential abundance. We assessed the accuracy of the system with a four-protein mixture at known ratios spanning a -fold change expression range of 1–4. From this, we proposed a methodology to address the accuracy issues of iTRAQ.     

Conformational cycling in beta-phosphoglucomutase catalysis: reorientation of the beta-D-glucose 1,6-(Bis)phosphate intermediate

Activated Lactococcus lactis beta-phosphoglucomutase (betaPGM) catalyzes the conversion of beta-d-glucose 1-phosphate (betaG1P) derived from maltose to beta-d-glucose 6-phosphate (G6P). Activation requires Mg(2+) binding and phosphorylation of the active site residue Asp8. Initial velocity techniques were used to define the steady-state kinetic constants k(cat) = 177 +/- 9 s(-)(1), K(m) = 49 +/- 4 microM for the substrate betaG1P and K(m) = 6.5 +/- 0.7 microM for the activator beta-d-glucose 1,6-bisphosphate (betaG1,6bisP). The observed transient accumulation of [(14)C]betaG1,6bisP (12% at approximately 0.1 s) in the single turnover reaction carried out with excess betaPGM (40 microM) and limiting [(14)C]betaG1P (5 microM) and betaG1,6bisP (5 microM) supported the role of betaG1,6bisP as a reaction intermediate in the conversion of the betaG1P to G6P. Single turnover reactions of [(14)C]betaG1,6bisP with excess betaPGM were carried out to demonstrate that phosphoryl transfer rather than ligand binding is rate-limiting and to show that the betaG1,6bisP binds to the active site in two different orientations (one positioning the C(1)phosphoryl group for reaction with Asp8, and the other orientation positioning the C(6)phosphoryl group for reaction with Asp8) with roughly the same efficiency. Single turnover reactions carried out with betaPGM, [(14)C]betaG1P, and unlabeled betaG1,6bisP demonstrated complete exchange of label to the betaG1,6bisP during the catalytic cycle. Thus, the reorientation of the betaG1,6bisP intermediate that is required to complete the catalytic cycle occurs by diffusion into solvent followed by binding in the opposite orientation. Published X-ray structures of betaG1P suggest that the reorientation and phosphoryl transfer from betaG1,6bisP occur by conformational cycling of the enzyme between the active site open and closed forms via cap domain movement. Last, the equilibrium ratio of betaG1,6bisP to betaG1P plus G6P was examined to evidence a significant stabilization of betaPGM aspartyl phosphate.